Skip to main content
Figure 2 | Experimental Hematology & Oncology

Figure 2

From: Quantification of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) using amplicon-fusion-site polymerase chain reaction (AFS-PCR)

Figure 2

Comparison of MRD values to different time points during therapy estimated by FACS-analysis, routine IgH/TCR-qPCR and AFS-PCR. (a) Calculated tumor cell numbers within the bone marrow from the day of the initial diagnosis, day 15 and day-29 respectively. (b) Calculated tumor cell numbers within the bone marrow from the day of the initial diagnosis and the two bone marrow aspirates at day 513 and day-533 respectively. For AFS-PCR tumor cell contents of the different bone marrow aspirates are quantified according to the 2-ΔΔCt calculation method. Each PCR was performed in triplicate. Mean values and standard deviations are indicated by dots and horizontal bars, respectively.

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us